213 related articles for article (PubMed ID: 11340581)
1. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
Cassinelli G; Supino R; Perego P; Polizzi D; Lanzi C; Pratesi G; Zunino F
Int J Cancer; 2001 Jun; 92(5):738-47. PubMed ID: 11340581
[TBL] [Abstract][Full Text] [Related]
2. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
[TBL] [Abstract][Full Text] [Related]
3. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
4. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel.
Kolfschoten GM; Hulscher TM; Duyndam MC; Pinedo HM; Boven E
Biochem Pharmacol; 2002 Feb; 63(4):733-43. PubMed ID: 11992642
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
6. UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites occur independently of p53-replication protein A interaction in p53 wild type and mutant ovarian carcinoma cells.
Riva F; Zuco V; Vink AA; Supino R; Prosperi E
Carcinogenesis; 2001 Dec; 22(12):1971-8. PubMed ID: 11751427
[TBL] [Abstract][Full Text] [Related]
7. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.
Lanzi C; Cassinelli G; Cuccuru G; Supino R; Zuco V; Ferlini C; Scambia G; Zunino F
Prostate; 2001 Sep; 48(4):254-64. PubMed ID: 11536305
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
[TBL] [Abstract][Full Text] [Related]
13. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
16. IDN 5390: an oral taxane candidate for protracted treatment schedules.
Pratesi G; Laccabue D; Lanzi C; Cassinelli G; Supino R; Zucchetti M; Frapolli R; D'Incalci M; Bombardelli E; Morazzoni P; Riva A; Zunino F
Br J Cancer; 2003 Mar; 88(6):965-72. PubMed ID: 12644838
[TBL] [Abstract][Full Text] [Related]
17. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
[TBL] [Abstract][Full Text] [Related]
19. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
20. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
Petrangolini G; Cassinelli G; Pratesi G; Tortoreto M; Favini E; Supino R; Lanzi C; Belluco S; Zunino F
Br J Cancer; 2004 Apr; 90(7):1464-8. PubMed ID: 15054472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]